Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MarketBeat

Why Conagra’s Dividend Cut Could Be the Best Thing for Investors

Conagra's dividend cut frees up $335 million annually for debt reduction and brand investment, supporting a turnaround as institutions accumulate shares despite a cautious analyst consensus.

Why ASML’s AI Monopoly Is Still Getting Stronger

Why ASML’s AI Monopoly Is Still Getting Stronger

ASML's Q2 results showed strong revenue growth, expanding margins, and raised guidance, prompting analyst price target increases, though geopolitical risks and valuation remain concerns.

Alphabet’s AI Spending Question Looms Over Q2 Earnings

Alphabet’s AI Spending Question Looms Over Q2 Earnings

Alphabet reports Q2 2026 earnings July 22, with analysts eyeing Google Cloud growth, a $462 billion backlog, Search resilience, and rising CapEx guidance as key catalysts.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet

Fastenal shares dipped after Q2 earnings matched forecasts, but revenue grew nearly 15%, margins held steady, and analysts and institutions remain supportive of the stock.

These 3 Stocks Are Beating the Market in 2026 and Just Announced Hefty Dividend Increases

Levi Strauss, Ryder System and Unum Group each raised dividends and are outperforming the S&P 500 in 2026, offering higher yields with well-supported payout ratios.

CEOs Sell Millions Worth of These 3 Big Name Stocks—What It Means for Investors

CEOs at Casey's, Rocket Lab and RH sold millions in shares recently, but context suggests the moves reflect diversification rather than clear bearish signals for investors.

Why Micron Is Doubling Down While the HBM Shortage Persists

Micron plans $250 billion in U.S. investment amid a persistent HBM shortage, as analysts maintain a Buy consensus and see substantial upside in the stock's valuation.

inkl

Read news from The Economist, FT, and more,
with one subscription

Analysts See Major Upside for These 5 Stocks

Analysts See Major Upside for These 5 Stocks

NVIDIA, Vistra, Mastercard, Micron, and Energy Transfer carry Buy ratings, high MarketRank scores, and double-digit analyst-implied upside ahead of earnings season.

AMD's 5C Deal Positions It as a Direct NVIDIA Rival

AMD's 5C Deal Positions It as a Direct NVIDIA Rival

AMD's 5C data center partnership positions it as a full-stack AI competitor to NVIDIA, with analysts citing strong price targets, growing coverage, and hypergrowth revenue forecasts ahead.

Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs

Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs

Microsoft is routing some Copilot prompts to its in-house MAI models to cut reliance on OpenAI and Anthropic, aiming to boost margins as MSFT shares trade off 2026 lows.

Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing

Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing

Delta Air Lines posted strong Q2 2026 results and raised guidance, driven by demand and premiumization, with analysts holding a Moderate Buy rating and price targets up to $110-$116.

Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks

Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks

Michael Burry bought DraftKings and Flutter shares, betting regulation will curb prediction markets like Kalshi, as Wall Street analysts also see both sportsbook stocks as undervalued.

Why WD-40 Is Proving Great Businesses Never Go Out of Style

Why WD-40 Is Proving Great Businesses Never Go Out of Style

WD-40's fiscal Q3 revenue rose 24% and guidance increased, sending shares to a multi-year high. Analysts hold a Buy consensus with a $305 price target, and a new $100 million buyback was authorized.

MarketBeat Week in Review – 07/06 - 07/10

MarketBeat Week in Review – 07/06 - 07/10

MarketBeat recaps the week's top stories, covering SK Hynix's debut, AI stock rotation, earnings from D.R. Horton, and analysis of Palantir, Microsoft, Meta, Broadcom, Rivian, ASML, and Circle.

Get all your
news in one place.

100's of premium titles.
One news app.

PepsiCo’s Dividend Could Turn Patience Into Real Profit

PepsiCo's Q2 revenue topped estimates and guidance was reaffirmed despite margin pressure, with analysts holding a Hold rating as the stock trades below its historical valuation average.

PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth

PriceSmart posted 12.5% revenue growth in fiscal Q3, plans six new clubs including its first in Chile, and shows a bullish stock chart pattern despite a high valuation.

Why Levi's Digital Strategy Is Paying Off in a Big Way

Levi's posted an 8% revenue rise to $1.56 billion in Q2, raised its guidance and dividend by 14%, and analysts maintain a Moderate Buy rating despite a post-earnings stock pullback.

Sony Is Going All-Digital—But Investors Should Watch This Instead

Sony will phase out physical gaming discs by 2028, raising memory-cost and ownership concerns, while SONY stock shows limited upside with a $22 consensus price target.

Get all your
news in one place.

100's of premium titles.
One news app.

Why Penguin Solutions May Be the Smartest AI Infrastructure Stock

Penguin Solutions posted a nearly 48% revenue jump and raised guidance in fiscal Q3, prompting analysts to lift price targets amid strong institutional buying and a rallying stock.

3 Beaten-Down Trades That Could Pay Off in a Market Correction

Chris Rowe of True Market Insiders sees signs of a possible market correction and is positioning in GDXJ, XME and Battalion Oil to play a rotation into oversold metals and an oil headline hedge.

5 Dividend Kings to Buy in July with Irristable Value and Yield

Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

Drone Stocks Are Down, But Defense Backlogs Tell a Different Story

AeroVironment, Red Cat Holdings, and Kratos Defense stocks have fallen in 2026 despite growing backlogs, funded contracts, and analyst price targets suggesting significant upside ahead.

SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade

SK Hynix's Nasdaq listing could raise $28 billion. The company trades at a discount to Micron, even as Micron expands HBM4 capacity and retains strong buy ratings from analysts amid AI memory demand.

AI Insider Activity: Are Sales Across 3 Key Stocks Noteworthy or Just Noise?

Insiders at Alibaba, Cerebras Systems and CoreWeave have sold AI-related shares recently, with CoreWeave's $3.27 billion Q2 total raising the most concern among the three companies.

1 2 3 4 5

People

Jeffrey Neal Johnson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

396,792 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play